TellWell
← Misinformation tracker
Partially FalseNews · Health

Partially False: Bexsero Protects Against Many Meningitis B Strains — But 'Most' Depends Heavily on Where You Live

The Bexero vaccine protects against most strains of meningitis B bacteria

The argument in brief

The claim that Bexsero protects against most strains of meningitis B bacteria is an oversimplification. Coverage varies widely by country — from under 50% in some regions to over 90% in others — and real-world effectiveness studies put protection at around 52–59% in UK infants. The vaccine is genuinely valuable, but blanket reassurances about 'most strains' don't hold up everywhere.

The numbersEstimated Bexsero (4CMenB) Strain Coverage by Country (MATS Analysis)

Data: Lancet Infectious Diseases / MATS studies, 2013-2019

Why it spread

Parents understandably want clear answers about protecting their children from a terrifying disease. Health messaging sometimes leans into optimistic shorthand like 'most strains' to encourage uptake, and that language gets repeated and shared without the important small print about where and how well the vaccine actually works.

The claim is that Bexsero, the meningococcal B vaccine, protects against most strains of meningitis B bacteria. The reality is more complicated: protection is meaningful and sometimes substantial, but whether it covers 'most' strains depends entirely on which country you're in and which bacterial strains are circulating there.

Bexsero works by targeting four proteins found on the surface of many meningococcal B bacteria. The problem is that not all strains carry these proteins in the same way. According to the European Medicines Agency's assessment, predicted strain coverage in the UK sits around 73–88% — that's a reasonable claim to 'most.' But a systematic review published in the journal Vaccine found coverage dropping below 50% in some regions, meaning the vaccine could miss more strains than it catches depending on where you are.

Real-world data adds another layer of caution. Public Health England found actual vaccine effectiveness in UK infants at roughly 52–59% — lower than the lab-based predictions suggest. That's still a meaningful reduction in a devastating disease, but it's a long way from comprehensive protection.

The CDC is clear that no meningitis B vaccine covers all strains, and the NHS carefully avoids claiming Bexsero protects against 'most' strains universally. There's also a separate issue the claim ignores entirely: Bexsero only targets serogroup B bacteria. It offers zero protection against meningococcal groups A, C, W, or Y, or other bacterial causes of meningitis altogether.

This kind of misinformation spreads partly because health communicators — with good intentions — reach for simple, reassuring language when talking to worried parents. 'Protects against most strains' sounds clear and comforting. The geographic and strain-specific caveats that actually define the evidence get left behind. Watch for vaccine claims that don't specify a region or population — that missing context often changes the picture significantly.

Sources

  • European Medicines Agency (EMA) - Bexsero Assessment Report

    Bexsero (4CMenB) was developed to provide broad coverage against meningococcal group B strains, but coverage varies by geographic region. The MATS (Meningococcal Antigen Typing System) assay estimated coverage of approximately 73-88% of UK MenB strains, but lower coverage in other regions.

  • Public Health England / UKHSA - Bexsero effectiveness study

    Real-world vaccine effectiveness of Bexsero against MenB disease in UK infants was estimated at around 52-59% in early studies, suggesting protection is meaningful but not comprehensive against all circulating strains.

  • Lancet Infectious Diseases - Bexsero coverage analysis

    MATS analysis across multiple countries found predicted strain coverage ranged from 66% to 91% depending on the country, indicating substantial but not universal protection against MenB strains globally.

  • CDC - Meningococcal Vaccines Information

    Bexsero targets four antigens (fHbp, NHBA, NadA, PorA P1.4) found in many but not all MenB strains. The CDC notes that no MenB vaccine covers all strains, and coverage depends on antigen expression in circulating bacteria.

  • Vaccine journal - Bexsero global strain coverage review

    A systematic review found that Bexsero's predicted coverage of MenB strains varied widely internationally, from under 50% in some regions to over 85% in others, meaning 'most strains' is not universally accurate.

  • NHS UK - Meningitis B vaccine overview

    The NHS states Bexsero offers protection against many strains of meningococcal group B bacteria, but does not claim protection against all or even most strains universally, and does not protect against other meningococcal groups (A, C, W, Y).

TellWell AI

Related debunks